119 related articles for article (PubMed ID: 12555072)
1. Characterization of the common fragile site FRA9E and its potential role in ovarian cancer.
Callahan G; Denison SR; Phillips LA; Shridhar V; Smith DI
Oncogene; 2003 Jan; 22(4):590-601. PubMed ID: 12555072
[TBL] [Abstract][Full Text] [Related]
2. Transcriptional profiling reveals that several common fragile-site genes are downregulated in ovarian cancer.
Denison SR; Becker NA; Ferber MJ; Phillips LA; Kalli KR; Lee J; Lillie J; Smith DI; Shridhar V
Genes Chromosomes Cancer; 2002 Aug; 34(4):406-15. PubMed ID: 12112530
[TBL] [Abstract][Full Text] [Related]
3. Evidence that instability within the FRA3B region extends four megabases.
Becker NA; Thorland EC; Denison SR; Phillips LA; Smith DI
Oncogene; 2002 Dec; 21(57):8713-22. PubMed ID: 12483524
[TBL] [Abstract][Full Text] [Related]
4. Common fragile sites, extremely large genes, neural development and cancer.
Smith DI; Zhu Y; McAvoy S; Kuhn R
Cancer Lett; 2006 Jan; 232(1):48-57. PubMed ID: 16221525
[TBL] [Abstract][Full Text] [Related]
5. Frequent deletions within FRA7G at 7q31.2 in invasive epithelial ovarian cancer.
Huang H; Reed CP; Mordi A; Lomberk G; Wang L; Shridhar V; Hartmann L; Jenkins R; Smith DI
Genes Chromosomes Cancer; 1999 Jan; 24(1):48-55. PubMed ID: 9892108
[TBL] [Abstract][Full Text] [Related]
6. Molecular characterization of the human common fragile site FRA1H.
Curatolo A; Limongi ZM; Pelliccia F; Rocchi A
Genes Chromosomes Cancer; 2007 May; 46(5):487-93. PubMed ID: 17311248
[TBL] [Abstract][Full Text] [Related]
7. Non-random inactivation of large common fragile site genes in different cancers.
McAvoy S; Ganapathiraju SC; Ducharme-Smith AL; Pritchett JR; Kosari F; Perez DS; Zhu Y; James CD; Smith DI
Cytogenet Genome Res; 2007; 118(2-4):260-9. PubMed ID: 18000379
[TBL] [Abstract][Full Text] [Related]
8. Altered expression and loss of heterozygosity of the LOT1 gene in ovarian cancer.
Cvetkovic D; Pisarcik D; Lee C; Hamilton TC; Abdollahi A
Gynecol Oncol; 2004 Dec; 95(3):449-55. PubMed ID: 15581945
[TBL] [Abstract][Full Text] [Related]
9. Global analysis of chromosome X gene expression in primary cultures of normal ovarian surface epithelial cells and epithelial ovarian cancer cell lines.
Benoît MH; Hudson TJ; Maire G; Squire JA; Arcand SL; Provencher D; Mes-Masson AM; Tonin PN
Int J Oncol; 2007 Jan; 30(1):5-17. PubMed ID: 17143508
[TBL] [Abstract][Full Text] [Related]
10. Differential loss of expression of common fragile site genes between oral tongue and oropharyngeal squamous cell carcinomas.
Soderberg C; Perez DS; Ukpo OC; Liang X; O'Reilly AG; Moore EJ; Kademani D; Smith DI
Cytogenet Genome Res; 2008; 121(3-4):201-10. PubMed ID: 18758160
[TBL] [Abstract][Full Text] [Related]
11. Stably transfected common fragile site sequences exhibit instability at ectopic sites.
Ragland RL; Glynn MW; Arlt MF; Glover TW
Genes Chromosomes Cancer; 2008 Oct; 47(10):860-72. PubMed ID: 18615677
[TBL] [Abstract][Full Text] [Related]
12. Loss of heterozygosity and transcriptome analyses of a 1.2 Mb candidate ovarian cancer tumor suppressor locus region at 17q25.1-q25.2.
Presneau N; Dewar K; Forgetta V; Provencher D; Mes-Masson AM; Tonin PN
Mol Carcinog; 2005 Jul; 43(3):141-54. PubMed ID: 15937959
[TBL] [Abstract][Full Text] [Related]
13. Biallelic deletion and loss of expression analysis of genes at FRA2G common fragile site in tumor-derived cell lines.
Limongi ZM; Curatolo A; Pelliccia F; Rocchi A
Cancer Genet Cytogenet; 2005 Sep; 161(2):181-6. PubMed ID: 16102592
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the candidate 8p21 tumour suppressor, BNIP3L, in breast and ovarian cancer.
Lai J; Flanagan J; Phillips WA; Chenevix-Trench G; Arnold J
Br J Cancer; 2003 Jan; 88(2):270-6. PubMed ID: 12610513
[TBL] [Abstract][Full Text] [Related]
15. Loss of heterozygosity at chromosome 9q22-31 is a frequent and early event in ovarian tumors.
Byrom J; Mudaliar V; Redman CW; Jones P; Strange RC; Hoban PR
Int J Oncol; 2004 May; 24(5):1271-7. PubMed ID: 15067351
[TBL] [Abstract][Full Text] [Related]
16. The characterization of the common fragile site FRA16D and its involvement in multiple myeloma translocations.
Krummel KA; Roberts LR; Kawakami M; Glover TW; Smith DI
Genomics; 2000 Oct; 69(1):37-46. PubMed ID: 11013073
[TBL] [Abstract][Full Text] [Related]
17. Chromosomal fragile sites FRA3B and FRA16D show correlated expression and association with failure of apoptosis in lymphocytes from patients with thyroid cancer.
Sbrana I; Veroni F; Nieri M; Puliti A; Barale R
Genes Chromosomes Cancer; 2006 May; 45(5):429-36. PubMed ID: 16419058
[TBL] [Abstract][Full Text] [Related]
18. Characterization of FRA6E and its potential role in autosomal recessive juvenile parkinsonism and ovarian cancer.
Denison SR; Callahan G; Becker NA; Phillips LA; Smith DI
Genes Chromosomes Cancer; 2003 Sep; 38(1):40-52. PubMed ID: 12874785
[TBL] [Abstract][Full Text] [Related]
19. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation.
Feng W; Marquez RT; Lu Z; Liu J; Lu KH; Issa JP; Fishman DM; Yu Y; Bast RC
Cancer; 2008 Apr; 112(7):1489-502. PubMed ID: 18286529
[TBL] [Abstract][Full Text] [Related]
20. Common chromosomal fragile site FRA16D mutation in cancer cells.
Finnis M; Dayan S; Hobson L; Chenevix-Trench G; Friend K; Ried K; Venter D; Woollatt E; Baker E; Richards RI
Hum Mol Genet; 2005 May; 14(10):1341-9. PubMed ID: 15814586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
